GET DAILY SIGNALSAbbVie (ABBV) Delivers +strong performance Over 30 Days on Acquisition and Pipeline Strength
Key Takeaways
- AbbVie shares surged approximately 17.6% over the past 30 days, climbing from $215.40 on May 27, 2026, to $253.35 at the June 26 close, hitting a new all-time high.
- The rally was fueled by the announced $10.9 billion acquisition of Apogee Therapeutics, strengthening AbbVie's immunology pipeline with an experimental eczema drug.
- Regulatory wins, including EU approval for pediatric Skyrizi and expanded Maviret use, reinforced confidence in AbbVie's product portfolio.
- Over the broader quarter, ABBV gained approximately 16.5%, reflecting sustained momentum driven by M&A activity, pipeline progress, and favorable analyst revisions.
- Wall Street analysts remain predominantly bullish, with 16 Buy ratings and 6 Hold ratings, and a consensus 12-month price target near $258.
AbbVie (ABBV) Company Overview and Market Position
AbbVie is a global, research-driven biopharmaceutical company headquartered in North Chicago, Illinois. Originally spun off from Abbott Laboratories in 2013, AbbVie has grown into one of the world's largest pharmaceutical companies by revenue, ranking sixth among biomedical firms. The company's portfolio spans immunology, oncology, aesthetics, neuroscience, and eye care. Its flagship immunology franchise — anchored by Humira, Skyrizi, and Rinvoq — remains a cornerstone of revenue, while oncology products such as Imbruvica and Venclexta contribute meaningfully. The 2020 acquisition of Allergan added Botox and a robust aesthetics business, and more recent deals, including the 2024 acquisitions of Cerevel Therapeutics and ImmunoGen, have expanded AbbVie's neuroscience and oncology capabilities. With a market capitalization exceeding $447 billion, AbbVie is a widely held dividend-paying stock followed closely by institutional and retail investors alike.
AbbVie (ABBV) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, AbbVie stock delivered a powerful rally, rising from a closing price of $215.40 on May 27, 2026, to $253.35 on June 26, 2026 — a gain of approximately 17.6%. The move was punctuated by a sharp 6.2% single-day surge on June 22 following the Apogee Therapeutics acquisition announcement, and the stock continued climbing through the final week of June to set a new all-time high. Trading volume spiked significantly during key sessions, reflecting strong institutional participation. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Zooming out to the quarterly view, ABBV has posted a gain of roughly 16.5% since the end of March 2026, when shares closed at $217.49 on March 31. The quarter began with some choppiness — the stock dipped as low as $190.75 intraday on April 29 following mixed Q1 2026 earnings — but recovered steadily through May and accelerated sharply in June. The quarterly performance underscores a broader trend of investor confidence returning to large-cap pharmaceutical names with strong pipelines and strategic growth initiatives.
What Drove ABBV Stock Price in the Last 30 Days
The primary catalyst behind AbbVie's 30-day surge was the announcement on June 22 that the company would acquire APGE (Apogee Therapeutics) for approximately $10.9 billion. Apogee is a clinical-stage biotechnology company developing next-generation antibody therapies for inflammatory diseases, including an experimental treatment for atopic dermatitis (eczema). Analysts at Canaccord Genuity, Scotiabank, Piper Sandler, and Morgan Stanley reiterated Buy ratings following the deal, citing strengthened long-term growth prospects in immunology — AbbVie's most critical therapeutic area.
Additional regulatory momentum added fuel. The European Commission approved Skyrizi (risankizumab) for pediatric use in psoriatic disease and expanded the label for Maviret, AbbVie's hepatitis C treatment. Meanwhile, the company and its partner filed regulatory submissions with the FDA and EMA for upadacitinib (Rinvoq) in new indications, further broadening the drug's addressable market.
Broader sector sentiment also played a role. Healthcare and biotechnology stocks experienced a wave of M&A-driven enthusiasm in June, with UBS analysts noting a surge in biotech dealmaking. AbbVie, already viewed as a defensive large-cap name with a 2.7% dividend yield, benefited from rotation into healthcare as technology shares faced intermittent selling pressure. The stock's low beta of approximately 0.27 also attracted risk-averse capital during periods of broader market uncertainty.
What Drove ABBV Stock Performance Over the Last Quarter
AbbVie's quarterly performance was shaped by a recovery narrative that took hold after a volatile start. In late April, the company reported Q1 2026 results: revenue of $15.0 billion beat consensus estimates of $14.72 billion, though adjusted earnings per share of $2.65 narrowly missed the $2.67 consensus. The initial reaction sent shares below $191, but the sell-off proved short-lived as investors focused on the revenue beat and management's reaffirmed full-year guidance.
Throughout May, AbbVie shares steadily recovered as the market digested positive clinical data updates, analyst upgrades, and growing confidence in the post-Humira growth story. Skyrizi and Rinvoq continued to demonstrate strong prescription growth, offsetting biosimilar erosion to Humira. The quarter's defining moment, however, was the Apogee acquisition in late June, which crystallized AbbVie's commitment to defending and expanding its immunology leadership. By quarter-end, the stock had not only recovered its April losses but surged to record territory.
ABBV Stock Forecast Drivers: What Investors Should Watch Next
Looking ahead, several factors will shape AbbVie's stock trajectory. The company is scheduled to report second-quarter 2026 earnings on July 31, and investors will closely scrutinize Skyrizi and Rinvoq revenue growth, Humira erosion trends, and any updated guidance. Integration planning for the Apogee acquisition and potential regulatory milestones for pipeline assets — including upadacitinib label expansions — will remain in focus. Macroeconomic conditions, including interest rate policy and healthcare sector rotation dynamics, may also influence institutional positioning. Additionally, competitive developments from peers such as LLY (Eli Lilly), JNJ (Johnson & Johnson), and AMGN (Amgen) in the immunology and oncology spaces warrant monitoring. While analyst sentiment remains broadly constructive, with price targets ranging from $230 to $298, investors should remain attentive to execution risks and broader market volatility.
Trending AI Robots
For traders seeking to navigate fast-moving stocks like AbbVie with data-driven precision, Tickeron's Trending AI Robots page offers a curated selection of top-performing AI-powered trading bots. Tickeron hosts hundreds of automated trading bots that actively trade thousands of tickers across diverse strategies, timeframes, and market conditions. Only the most relevant and consistently high-performing bots are featured in the Trending section, giving users a streamlined view of strategies that have demonstrated real-time effectiveness. Whether focused on short-term swing trades, trend-following, or pattern recognition, these AI robots provide actionable signals backed by technical and fundamental analysis. Explore the Trending AI Robots page to see which strategies are currently leading the market.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.
ABBV's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for ABBV turned positive on October 07, 2026. Looking at past instances where ABBV's MACD turned positive, the stock continued to rise in 32 of 46 cases over the following month. The odds of a continued upward trend are 70%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 05, 2026. You may want to consider a long position or call options on ABBV as a result. In 52 of 77 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 68%.
Following a +3.11% 3-day Advance, the price is estimated to grow further. Considering data from situations where ABBV advanced for three days, in 217 of 356 cases, the price rose further within the following month. The odds of a continued upward trend are 61%.
The Aroon Indicator entered an Uptrend today. In 224 of 351 cases where ABBV Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 64%.
Bearish Trend Analysis
The 10-day RSI Indicator for ABBV moved out of overbought territory on November 02, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 43 similar instances where the indicator moved out of overbought territory. In 14 of the 43 cases, the stock moved lower in the following days. This puts the odds of a move lower at 33%.
The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ABBV declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 46%.
ABBV broke above its upper Bollinger Band on October 07, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is 1 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 3 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: ABBV's P/B Ratio (-86.001) is very low in comparison to the industry average of (-1.476). ABBV has a moderately high P/E Ratio (81.593) as compared to the industry average of (21.871). Projected Growth (PEG Ratio) (0.544) is also within normal values, averaging (5.738). Dividend Yield (0.024) settles around the average of (0.038) among similar stocks. ABBV's P/S Ratio (7.231) is slightly higher than the industry average of (4.033).
The Tickeron Profit vs. Risk Rating rating for this company is 3 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 60, placing this stock better than average.
The Tickeron Price Growth Rating for this company is 9 (best 1 - 100 worst), indicating outstanding price growth. ABBV’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 30 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 89 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a research-based pharmaceutical company
Industry PharmaceuticalsMajor
Advertisement